Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label single-arm study of equecabtagene autoleucel in immune-mediated necrotizing myopathy
CTR20263410Phase 2Active
- Sponsor
- Reindeer Biotech
- Start
- Sep 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of equecabtagene autoleucel in immune-mediated necrotizing myopathy (IMNM), sponsored by Reindeer Biotech. Started Sep 2026; status: active.
02
Drugs
equecabtagene autoleucel
03
Conditions
immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on CTR20263410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263410.